Sakitamiwa Classification [patched] May 2026
Understanding the Sakitamiwa Classification: A Comprehensive Guide
In the evolving landscape of medical diagnostics and clinical terminology, few systems have garnered as much niche yet critical attention as the Sakitamiwa Classification. While not a household name, this classification system plays a pivotal role in specific branches of pathology, risk assessment, and therapeutic stratification. If you have encountered this term in a clinical study, a lecture, or a diagnostic report, this guide will provide you with a thorough understanding of its origins, categories, applications, and clinical significance.
Comparative Trial: Randomised clinical trial: tegoprazan or lansoprazole in the treatment of gastric ulcer in Alimentary Pharmacology & Therapeutics (2020). sakitamiwa classification
- S – Shock (MAP < 65) → Stage III/IV
- A – Ascites / Albuminuria → Stage II
- K – Kidney injury (creatinine x2) → Stage II/III
- I – Intracerebral bleed or altered sensorium → Stage III/IV
- T – Thrombocytopenia (< 50,000) + Tourniquet test (+) → Stage II
- A – Asymptomatic → Stage 0 or I
: It is frequently used to monitor "artificial ulcers" created during Endoscopic Submucosal Dissection (ESD) S – Shock (MAP < 65) → Stage
2.2. Symptomatology
The classification of Sakitamiwa is syndrome-based rather than pathogen-based. Common symptoms traditionally associated with this classification include: : It is frequently used to monitor "artificial
Vascular tumors